Guild of Guides Netherlands and the Future of Professional Psychedelics

As global interest in Dutch retreats grows, psilocybin truffle guides and groups have come together to establish self-regulation and best practices for those who offer guided tripping.

New Study Shows Ayahuasca’s Benefits When Used in a Traditional Setting

A new study investigating ayahuasca’s effects when taken within Shipibo-style ceremonies finds a significant decrease in neuroticism.

Pioneering Psychedelic Researcher Once Again Paves the Way with Historic Psilocybin Study for End of Life Patients

Researcher and professor Dr. Charles Grob discusses The Lundquist Institute’s announcement of a new multi-site clinical trial examining psilocybin for palliative care, the first study of its kind since the 1960’s, in this Q & A with Lucid News.

Psilocybin Shows Promise for OCD Treatment

A newly published review calls for more research into psilocybin’s potential to treat obsessive-compulsive disorder (OCD) based on promising findings and anecdotal reports.

American Adults Increase LSD Use By 56 Percent

LSD use in American adults rose over 50 percent between 2015 and 2018, a surge that one researcher attributes to rising national chaos.

60-Plus Psychedelic Clinical Trials Listed on Online Directory

A network of psychedelic healthcare providers offers a comprehensive global directory of psychedelic clinical trials that are actively enrolling.

To Prevent Corruption, Psychedelics Researchers Call for Ethics Guidelines

A group of Canadian researchers proposes clear guidelines for academic researchers to keep the field of psychedelic science transparent.

DARPA Funds $27 Million Project to Create Psychedelic-Inspired Psychiatric Drugs Without the Trip

Researchers at the University of North Carolina use new techniques to create medicines that duplicate the effectiveness of ketamine and psilocybin as treatments for depression without the psychoactive effects.

Eleusis Draws on Research Into Psychedelics To Develop New Medicines for Inflammation

The company is researching the anti-inflammatory properties of psychedelics to create new drugs with reduced psychoactivity.

Researcher Charles Nichols Studies the Impact of Psychedelic Substances on Inflammation

Critical research sponsored by the Eleusis Benefit Corporation could lead to new drugs for Alzeimers and Retinal Disease.